NasdaqGS - Nasdaq Real Time Price
USD
Indivior Pharmaceuticals, Inc. (INDV)
35.37
+0.12
(+0.34%)
At close: 4:00:01 PM EDT
35.37
0.00
(0.00%)
After hours: 4:00:15 PM EDT
Trade INDV on Coinbase
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreLoading chart for INDV
- Previous Close
35.25 - Open
34.78 - Bid 25.72 x 200
- Ask 44.80 x 200
- Day's Range
34.62 - 36.48 - 52 Week Range
27.68 - 42.81 - Volume
4,261,023 - Avg. Volume
2,401,026 - Market Cap (intraday)
4.175B - Beta (5Y Monthly) --
- PE Ratio (TTM)
12.68 - EPS (TTM)
2.79 - Earnings Date Oct 29, 2026
- Forward Dividend & Yield -- (0.00%)
- 1y Target Est
49.50 - Zacks Rating Neutral
Recent News
View More
Performance Overview
Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
INDV
1.42%
S&P 500 (^GSPC)
10.73%
1-Year Return
INDV
21.42%
S&P 500 (^GSPC)
11.11%
3-Year Return
INDV
80.46%
S&P 500 (^GSPC)
81.91%
5-Year Return
INDV
108.67%
S&P 500 (^GSPC)
64.59%
Earnings Trends
View MoreAnalyst Insights
View MoreStatistics
View MoreValuation Measures
As of 10/29/2026
-
Market Cap
4.16B
-
Enterprise Value
4.45B
-
Trailing P/E
12.63
-
Forward P/E
9.18
-
PEG Ratio (current)
0.47
-
Price/Sales (ttm)
3.41
-
Price/Book (mrq)
--
-
Enterprise Value/Revenue
3.34
-
Enterprise Value/EBITDA
10.56
Financial Highlights
Profitability and Income Statement
-
Profit Margin
32.75%
-
Return on Assets (ttm)
31.16%
-
Return on Equity (ttm)
--
-
Revenue (ttm)
1.37B
-
Net Income Avi to Common (ttm)
450M
-
Diluted EPS (ttm)
2.79
Balance Sheet and Cash Flow
-
Total Cash (mrq)
305M
-
Total Debt/Equity (mrq)
--
-
Levered Free Cash Flow (ttm)
245.12M
Compare
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
35.37
+0.34%
Mkt Cap
4.175B
Industry
Drug Manufacturers—Specialty & Generic
38.88
+0.05%
Mkt Cap
1.579B
Industry
Drug Manufacturers—Specialty & Generic
23.80
-0.96%
Mkt Cap
774.824M
Industry
Drug Manufacturers—Specialty & Generic
3.5000
-3.31%
Mkt Cap
578.34M
Industry
Drug Manufacturers—Specialty & Generic
92.24
-5.45%
Mkt Cap
7.247B
Industry
Drug Manufacturers—Specialty & Generic
84.00
-1.18%
Mkt Cap
TWD
5.611B
Industry
Drug Manufacturers—Specialty & Generic
23.06
-0.77%
Mkt Cap
11.521B
Industry
Drug Manufacturers—Specialty & Generic
6.40
-1.84%
Mkt Cap
242.597M
Industry
Drug Manufacturers—Specialty & Generic
41.92
+0.19%
Mkt Cap
2.441B
Industry
Drug Manufacturers—Specialty & Generic
28.86
+0.63%
Mkt Cap
3.622B
Industry
Drug Manufacturers—Specialty & Generic
72.00
-1.59%
Mkt Cap
1.654B
Industry
Drug Manufacturers—Specialty & Generic
Company Insights
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Learn more
Dividend Score
The distribution of earnings a company pays back to its shareholders based off the company’s profits. Usually paid out on a quarterly basis in the form of cash or additional stocks.
Hiring Score
A company’s hiring trends in key indicators can indicate how well the company is doing in terms of growing the company and where they are currently prioritizing.
Insider Sentiment Score
Vicker’s Insider Sentiment provides insights into trades made by insiders. This can be used to gain valuable insights and as a reflection of the prospect of the company based on insider trading.
Research Reports
View More-
What does Argus have to say about INDV?
Indivior Pharmaceuticals Inc has an Investment Rating of HOLD; a target price of $33.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of High; and a Value Subrating of Medium.
-
Lowering target price to $33.00
Indivior Pharmaceuticals Inc has an Investment Rating of HOLD; a target price of $33.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of High; and a Value Subrating of Medium.
-
Lowering target price to $34.00
Indivior Pharmaceuticals Inc has an Investment Rating of HOLD; a target price of $34.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of High; and a Value Subrating of High.
-
What does Argus have to say about INDV?
Indivior Pharmaceuticals Inc has an Investment Rating of HOLD; a target price of $38.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of High; and a Value Subrating of High.
